SPOTLIGHT: BMS, Exelixis extend pact


Exelixis and Bristol-Myers Squibb have extended their pact to develop and commercialize therapies targeted against the Liver X Receptor, a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic disorders. Release